Sound Biologics

Focus: Sound Biologics is a therapeutic antibody-focused biotech company headquartered in Bothell, WA, operating as a public company since 2015 with a concentrated focus on oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Sound Biologics

AI assessmentNot Hiring

No open roles listed right now. Follow Sound Biologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PSB205

Neoplasm Malignant

PHASE_1

PSB202

Follicular Lymphoma

PHASE_1

Clinical Trials (1)

Help build intelligence for Sound Biologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage antibody platform with potential to establish foundational IP in oncology immunotherapy — opportunity to build domain expertise in a growing modality
Public company status provides liquidity optionality and access to capital markets, reducing restructuring risk relative to pre-revenue peers
Focused oncology pipeline (follicular lymphoma, solid tumors) aligns with high-value therapeutic area with sustained funding momentum

Watch Out For

Both pipeline programs are in Phase 1 with no marketed products — limited near-term revenue catalysts or clinical proof-of-concept data to assess team execution
Zero active job openings and sparse published output (3 publications) suggest minimal hiring momentum and limited visibility into science quality or organizational scale
Complete absence of financial data (revenue, R&D spend, cash position) makes it impossible to assess runway, burn rate, or sustainability — classic early-stage risk

Generated by Claude from Sound Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.